Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema
Portfolio Pulse from Vandana Singh
Regeneron Pharmaceuticals announced two-year results from the PHOTON trial of aflibercept 8 mg, showing that fewer injections maintain vision and anatomic improvements in diabetic macular edema patients. The trial met its primary endpoint last year with aflibercept 8 mg patients achieving clinically equivalent vision gains to Eylea. Aflibercept 8 mg is being jointly developed by Regeneron and Bayer AG.
July 31, 2023 | 1:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bayer AG is jointly developing aflibercept 8 mg with Regeneron. The positive trial results could potentially increase the demand for the drug.
As a joint developer of aflibercept, Bayer AG could also benefit from the increased demand for the drug, which would positively impact its revenues and stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Regeneron's PHOTON trial results show that fewer aflibercept injections maintain vision and anatomic improvements in diabetic macular edema patients. This could potentially increase the demand for the drug.
The positive trial results could potentially increase the demand for aflibercept, which would positively impact Regeneron's revenues and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100